5-Amino-1MQ

5-Amino-1MQ (also known as 5-amino-1-methylquinolinium) is a performance-enhancing peptide studied for its effects on fat loss, weight loss, metabolic health. 5-Amino-1MQ is an oral NNMT inhibitor studied in rodents for fat loss and raising NAD+. No human trials; prohibited by WADA under class S0.

5-Amino-1MQ is an orally bioavailable small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that consumes nicotinamide and S-adenosyl methionine to produce 1-methylnicotinamide. Blocking NNMT is intended to raise intracellular NAD+ and S-adenosyl methionine, especially in adipose tissue, where rodent work has reported increased fat-cell energy expenditure and reduced diet-induced obesity. Despite being sold and discussed alongside peptides, it is not a peptide but a methylquinolinium small molecule.

Overview

Human evidence is absent: there are no completed or active clinical trials, no regulatory approval in any jurisdiction, and every efficacy result to date comes from cell-culture or rodent models.

Because no governmental regulatory health authority has approved it for human therapeutic use, it falls under class S0 (non-approved substances) of the WADA Prohibited List, meaning 5-Amino-1MQ is prohibited by WADA at all times, both in and out of competition.

Mechanism of action

Oral small-molecule NNMT inhibitor that raises NAD+ and S-adenosyl methionine to boost fat-cell energy expenditure. Studied only in rodents for fat loss; no human trials exist.

Reported effects

Effects reported in the literature and from preclinical models include:

• Combined with a low-fat diet, 5-amino-1-methylquinolinium produced dramatic whole-body adiposity and weight loss in diet-induced obese mice, rapidly normalizing those measures to age-matched lean animals. ^[2] Preclinical
• A low-fat diet switch alone did not restore adiposity and body weight to age-matched control levels over the same period in diet-induced obese mice. ^[2] Preclinical
• Treated obese mice switched to a low-fat diet showed a distinct cecal microbiome pattern with decreased Erysipelatoclostridium and increased Lactobacillus relative abundances compared with vehicle counterparts. ^[2] Preclinical
• 5-Amino-1-methylquinolinium iodide significantly reduced tumor growth in urothelial bladder cancer mouse models. ^[1] Preclinical
• The compound enhanced the apoptotic effects of anti-PD-L1 antibody treatment in urothelial bladder cancer mouse models. ^[1] Preclinical

Evidence grades: FDA approvedApproved (non-US)Phase IIIPhase IIPhase IPreclinicalAnecdotal

Natty status

5-Amino-1MQ is classified as not natty. It appears on the WADA prohibited list and is banned by major natural bodybuilding federations.^[3] Use of this compound places the athlete in the enhanced category rather than the natural category in competitive contexts.

Research

The peptide has been the subject of 2 studies and reference works collected on this site.

Related compounds

Other peptides in this catalogue with overlapping mechanisms or status:

References

1. ^ a b NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. Recent
2. ^ a b c Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Recent
3. ^ a b World Anti-Doping Agency. (2026). Prohibited List 2026.

External links

• 50mg 5-Amino-1MQ — commercial